PTJA16 – Venetoclax in combination with an hypomethylating agent for treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy – final assessment now available
This is the pharmaceutical Joint Assessment PTJA16 – Venetoclax with a hypomethylating agent fort he treatment of adult patients with newly diagnosed acute myeloid leukaemia
EUnetHTA and EMA take stock of their cooperation
The European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA) have published a Technical Report on their achievements since 2017.
EUnetHTA-EMA April Meeting – minutes now available
We are pleased to publish the minutes for the EUnetHTA-EMA Bilateral meeting held online on 28 April, 2021. This meeting concluded the EMA/EUnetHTA work plan
PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed
PTJA17 – Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD) – project plan now available
The final project plan of the relative effectiveness assessment of ‘Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD)’ is now available for access. The
Engaging Stakeholder in Joint Action 3 – now available for access
As Joint Action 3 (JA3) comes to a close, an overview of stakeholder interaction has been prepared that focusses on who our stakeholders are, the
OTCA25 Final Report and related documents now available
The final report for the Relative Effectiveness Assessment OTCA 25 “Stereotactic body radiation therapy (SBRT) for the treatment of lung, prostate and liver cancer”, is
PTRCR19 – REGN-COV2 for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the third pharmaceutical Rapid Collaborative Review (PTRCR19) published by EUnetHTA. This report describes REGN-COV2 for the treatment of COVID-19 patients. In March 2021,
OTCA27 – Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)- final report now available
The final report is now available for the Relative Effectiveness Assessment OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic
EMA-EUnetHTA Bilateral Meeting held today.
The concluding EMA-EUnetHTA Bilateral Meeting under Joint Action 3 was held online today, marking a fitting conclusion to another stage of regular ongoing collaboration that